Skip To Main Content
William E. Barlow on Muck Rack

William E. Barlow

As seen in: The Telegraph, JAMA Oncology, The New England Journal of Medicine, The Lancet, MedPage Today, MarketScreener, Horse & Hound, Texas Medical Center, ONCOLOGY journal
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with William E.

Contact William E., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Strategic Equity Capital Plc

|
By William E. Barlow
| MarketScreener
By PRNewswire Strategic Equity Capital plc (the "Company") LEI: 2138003R5GB8QZU2G577 Directorate Changes As previously announced, William Barlow, the Chair of the Company, will retire from the Board at the conclusion of the 2026 Annual General Meeting, expected to be held in November 2026. The Board would like to take the opportunity to thank William for his long-term leadership and will miss his valued contribution.
Open in Who Shared View Duplicates (5) Issue with article?

Radiotherapy Use and Incidence of Locoregional Recurrence in Patients With Favorable-Risk, Node-Positive Breast Cancer Enrolled in the SWOG S1007 Trial

|
By Reshma Jagsi, William E. Barlow, Wendy A. Woodward, Eileen Connolly
| Texas Medical Center
IMPORTANCE: Little is known about regional nodal irradiation (RNI) practice patterns or rates of locoregional recurrence (LRR) with and without RNI in patients with limited nodal disease and favorable biology treated with modern surgical and systemic therapy, including approaches that de-escalate those latter treatments.
Open in Who Shared Issue with article?

Dual Prognostic Classification of Triple-Negative Breast Cancer by DNA Damage Immune Response and Homologous Recombination Deficiency

|
By Shane R. Stecklein, William E. Barlow, Lajos Pusztai, Kirsten M. Timms
CONTEXT Key Objective Triple-negative breast cancer (TNBC) is a heterogeneous disease. Multiple prognostic biomarkers have been identified and several classification systems have been described, although none of these are able to predict response to discrete therapeutic agents.
Open in Who Shared Issue with article?
See all 21 licensed articles (24 Total)